ClinicalTrials.Veeva

Menu

A Multi-center Study to Evaluate Bone Loss, Survival Rate and Stability of ICE Implant

A

Alpha-Bio Tec

Status and phase

Completed
Phase 4

Conditions

Implant Clinical Survival
Dental Implant Bone Loss

Treatments

Device: ICE dental implant

Study type

Interventional

Funder types

Industry

Identifiers

NCT01960361
ICE_001

Details and patient eligibility

About

The current prospective clinical study's aim is to determine ABT's ICE implant survival rate, crestal interproximal bone resorption during 24 months post implant insertion and to assimilate the drilling sequence during the clinical use of ICE implants.

Enrollment

35 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Men and women over the age of 18 years who need implantation of 1-4 implants.
  2. Patients who are able to understand the requirements of the study, and are willing and able to comply with its instructions and schedules.
  3. Patients who had provided written informed consent to participate in the study prior to any study procedure.
  4. Patients in general good health in the opinion of the principal investigator as determined by medical history and oral examination.

Exclusion criteria

  1. Immediate loaded implants.

  2. Treatment with anticoagulant drugs (INR under 1.8) or bisphosphonates.

  3. Treatment with anticonvulsants drugs.

  4. Untreated Periodontal disease and inability of the patient to maintain reasonable oral hygiene according to study requirements.

  5. Patients with history of alcohol, narcotics or drug abuse.

  6. Patients under steroid therapy.

  7. Patients receiving radiotherapy, chemotherapy or any other immunosuppressive treatment or who have been administered radiotherapy in the last 5 years.

    Patients through at anytime received radiotherapy to the head and neck region will be excluded anyway.

  8. Metabolic bone disorders and/or bone augmentation.

  9. Uncontrolled bleeding disorders such as: hemophilia, thrombocytopenia, granulocytopenia.

  10. Degenerative diseases.

  11. Osteoradionecrosis.

  12. Renal failure.

  13. Organ transplant recipients.

  14. HIV positive.

  15. Malignant diseases.

  16. Diseases that compromise the immune system.

  17. Unbalanced diabetes mellitus. (HbA1c above 6.5)

  18. Psychotic diseases.

  19. Hypersensitivity to one of the components of the implant in general and titanium in particular.

  20. Women who are pregnant or lactating.

  21. Lack of patient cooperation.

  22. Uncontrolled endocrine diseases.

  23. Any systemic condition that is unbalanced and therefore precludes surgical procedures.

  24. Parafunctional habits.- e.g Bruxism.

  25. Temporomandibular joint disease.

  26. Various pathologies of the oral mucosa for example: Benign mucous pemphigoid, desquamative ginigivitis, erosive lichen planus ,malignancy of oral cavity, bolus erosive diseases of the oral mucosa.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

35 participants in 1 patient group

ICE dental implant
Experimental group
Description:
Subjects implanted with ICE implant
Treatment:
Device: ICE dental implant

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems